UPDATE : Thursday, November 14, 2019
상단여백
Sillajen’s trouble heralds fall of one of most prominent biotech firms
Shares of Sillajen continued to take a nosedive Monday after the biotech fi...
by Lee Han-soo  |  2019-08-05 16:55
라인
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
SillaJen said Pexa-Vec, an oncolytic viral drug, still had significant pote...
by Jeong Sae-im  |  2019-08-05 14:49
라인
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
With the likely suspension of SillaJen’s trial on its major anticancer pipe...
by Jeong Sae-im  |  2019-08-05 11:26
라인
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
Local biotech shares went down altogether on Friday after SillaJen said it ...
by Jeong Sae-im  |  2019-08-02 15:45
라인
Eutilex pipelines are underrated: CEO
Eutilex CEO Kwon Byeong-se said he felt sorry for the recent fall of the co...
by Jeong Sae-im  |  2019-08-01 16:08
라인
Samsung BioLogics records Q2 operating loss
Samsung BioLogics logged an operating loss of 5.4 billion won ($13.1 millio...
by Lee Han-soo  |  2019-07-25 10:16
라인
Samsung Bioepis biosimilar sales in EU top $180 million in Q1
Samsung Bioepis’ sales in the European Union surpassed $180 million in the ...
by Lee Han-soo  |  2019-07-24 15:29
라인
Celltrion Healthcare joins Australia's pharma industry group
Celltrion Healthcare said that it has joined Australia's Generic and Bi...
by Lee Han-soo  |  2019-07-22 15:13
라인
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs
The accounting fraud allegation involving Samsung BioLogics has been one of...
by Lee Han-soo  |  2019-07-19 18:16
라인
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
Samsung Bioepis said that the European Medicines Agency (EMA) has started e...
by Lee Han-soo  |  2019-07-19 17:01
라인
Celltrion targets Chinese biosimilar market through joint venture
Celltrion said it has established Vcell Healthcare Ltd., a joint venture wi...
by Lee Han-soo  |  2019-07-19 14:53
라인
Biopharmaceutical stocks face grim outlook in 2H
Biopharmaceutical stocks remain sluggish in the second half. Stock prices h...
by Jeong Sae-im  |  2019-07-17 14:11
라인
Celltrion starts P1 trial of Xolair biosimilar
Celltrion said Monday that it initiated the phase 1 clinical trial of CT-P3...
by Lee Han-soo  |  2019-07-15 17:45
라인
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
Colon cancer specialists questioned SillaJen’s allegation that the combinat...
by Jeong Sae-im, Kim Yun-mi  |  2019-07-12 15:13
라인
Court suspends decision on ministry’s order to revoke Invossa license
The Seoul Administrative Court on Thursday said it has temporarily suspende...
by Jeong Sae-im  |  2019-07-12 13:11
라인
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
The prosecution raided two securities firms that managed the initial public...
by Jeong Sae-im  |  2019-07-11 16:39
라인
NKMax America seeks NASDAQ listing
“Seeking NASDAQ listing as soon as possible, we will show the excellent eff...
by Jeong Sae-im  |  2019-07-11 12:41
라인
Psomagen seeks KOSDAQ listing using technology exception policy
Psomagen, a U.S. subsidiary of Macrogen, said it would use Korea’s “technol...
by Jeong Sae-im  |  2019-07-10 15:20
라인
Kolon files administrative suit against Invossa license revocation
Kolon Life Science said it has filed an administrative lawsuit against the ...
by Jeong Sae-im  |  2019-07-09 11:47
라인
SillaJen shareholders panic over exec’s selling of 160,000 stocks
An executive at SillaJen suddenly sold 160,000 shares for “personal reasons...
by Jeong Sae-im  |  2019-07-09 11:45
여백
여백
여백
Back to Top